Targeted therapies expanding treatment options in metastatic thyroid cancer

👉Targeted therapies are expanding treatment options in metastatic thyroid cancer (MTC).

👉In the past 10 years, four VEGF inhibitors have been approved for MTC: sorafenib and lenvatinib for differentiated thyroid cancer, and cabozantinib and vandetanib for medullary thyroid cancer.

👉Cabozantinib and vandetanib are also moderate RET inhibitors.

👉In addition, larotrectinib was recently approved for all solid tumors that harbor TRK fusions, and patients with differentiated thyroid cancer are frequently TRK positive.

👉Consequently, knowing what genetic mutations a patient harbors can greatly affect the choice of therapies.

#Arrangoiz #ThyroidSurgeon #ThyroidExpert #CASO #CenterforAdvancedSurgicalOncology #PalmettoGeneralHospital

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s